A Phase I/II Study of Sorafenib (BAY 43-9006) in Combination With Low Dose ARA-C (Cytarabine) in Elderly Patients With AML [acute myeloid leukaemia] or High-Risk MDS [myelodysplastic syndrome]

Trial Profile

A Phase I/II Study of Sorafenib (BAY 43-9006) in Combination With Low Dose ARA-C (Cytarabine) in Elderly Patients With AML [acute myeloid leukaemia] or High-Risk MDS [myelodysplastic syndrome]

Completed
Phase of Trial: Phase I/II

Latest Information Update: 28 Mar 2016

At a glance

  • Drugs Sorafenib (Primary) ; Cytarabine
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Sep 2013 Additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 12 Dec 2009 Status changed from recruiting to completed as reported by National Cancer Institute of Canada.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top